UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

Journal of hepatology, 2015-03, Vol.62 (3), p.533-540

2015

Volltextzugriff (PDF)

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Journal of hepatology, 2017-08, Vol.67 (2), p.370-398

2017

Volltextzugriff (PDF)

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Annals of hepatology, 2016-07, Vol.15 (4), p.512-523

2016

Volltextzugriff (PDF)

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant

Annals of hepatology, 2017-05, Vol.16 (3), p.375-381

2017

Volltextzugriff (PDF)

Liver abnormalities in the immunosuppressed

Baillière's best practice & research. Clinical gastroenterology, 2013-08, Vol.27 (4), p.597-618

2013

Volltextzugriff (PDF)

Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Journal of hepatology, 2016-10, Vol.65 (4), p.741-747

2016

Volltextzugriff (PDF)

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial

Journal of hepatology, 2016-07, Vol.65 (1), p.33-39

2016

Volltextzugriff (PDF)

Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses

Journal of hepatology, 2017-08, Vol.67 (2), p.224-236

2017

Volltextzugriff (PDF)

Treatment of chronic hepatitis C virus infection after liver transplantation

Digestive and liver disease, 2013-09, Vol.45, p.S349-S354

2013

Volltextzugriff (PDF)

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Gastroenterology (New York, N.Y. 1943), 2015-11, Vol.149 (6), p.1462-1470

2015

Volltextzugriff (PDF)

Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis

Journal of hepatology, 2017-08, Vol.67 (2), p.263-271

2017

Volltextzugriff (PDF)

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Gastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.113-122

2017

Volltextzugriff (PDF)

Massive Gastrointestinal Bleed in a Patient With Primary Sclerosing Cholangitis

Gastroenterology (New York, N.Y. 1943), 2011-05, Vol.140 (5), p.e7-e8

2011

Volltextzugriff (PDF)

Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C

Gastroenterology (New York, N.Y. 1943), 2014-03, Vol.146 (3), p.744-753.e3

2014

Volltextzugriff (PDF)

812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1267-S1268

2016

Volltextzugriff (PDF)

Hepatitis B (HBV) Viral Suppression is Independently Associated with Better Patient-Reported Outcomes (PROS)

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1085-S1085

2017

Volltextzugriff (PDF)

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Journal of hepatology, 2015-06, Vol.62 (6), p.1246-1255

2015

Volltextzugriff (PDF)

Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1061-S1061

2017

Volltextzugriff (PDF)

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1085-S1086

2017

Volltextzugriff (PDF)

Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

Journal of hepatology, 2016

2016

Volltextzugriff (PDF)

A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results

Clinical gastroenterology and hepatology, 2017, Vol.15 (1), p.e44-e44

2017

Volltextzugriff (PDF)

Su1413 Sof/VEL for 12 Weeks Results in High SVR 12 Rates in Subjects With Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy Fron the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1092-S1092

2016

Volltextzugriff (PDF)

Sa1637 High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S1083-S1083

2016

Volltextzugriff (PDF)

Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-975-S-976

2014

Volltextzugriff (PDF)

Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-903-S-903

2014

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

ThemaGastroenterology And Hepatology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Gastroenterology & Hepatology
(13)
Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Male
(10)
Female
(9)
Middle Aged
(9)
Antiviral Agents - Therapeutic Use
(8)
Adult
(7)
Antiviral Agents - Adverse Effects
(7)
Drug Therapy, Combination
(7)
Genotype
(7)
Hepacivirus - Genetics
(7)
Hepatitis C, Chronic - Drug Therapy
(6)
Treatment Outcome
(6)
Aged
(5)
Antiviral Agents - Administration & Dosage
(5)
Hepacivirus - Drug Effects
(5)
Ribavirin - Therapeutic Use
(5)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant

Liver abnormalities in the immunosuppressed

Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial

Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses

Treatment of chronic hepatitis C virus infection after liver transplantation

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Massive Gastrointestinal Bleed in a Patient With Primary Sclerosing Cholangitis

Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C

812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial

Hepatitis B (HBV) Viral Suppression is Independently Associated with Better Patient-Reported Outcomes (PROS)

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study

Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results

Su1413 Sof/VEL for 12 Weeks Results in High SVR 12 Rates in Subjects With Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy Fron the ASTRAL-1, ASTRAL-2 and ASTRAL-3 Studies

Sa1637 High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies

Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)

Aktive Filter

Suchergebnisse filtern